GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CellaVision AB (LTS:0MR5) » Definitions » Cyclically Adjusted PB Ratio

CellaVision AB (LTS:0MR5) Cyclically Adjusted PB Ratio : 8.92 (As of May. 25, 2025)


View and export this data going back to 2016. Start your Free Trial

What is CellaVision AB Cyclically Adjusted PB Ratio?

As of today (2025-05-25), CellaVision AB's current share price is kr186.10. CellaVision AB's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was kr20.86. CellaVision AB's Cyclically Adjusted PB Ratio for today is 8.92.

The historical rank and industry rank for CellaVision AB's Cyclically Adjusted PB Ratio or its related term are showing as below:

LTS:0MR5' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 7.32   Med: 29.27   Max: 53.92
Current: 8.98

During the past years, CellaVision AB's highest Cyclically Adjusted PB Ratio was 53.92. The lowest was 7.32. And the median was 29.27.

LTS:0MR5's Cyclically Adjusted PB Ratio is ranked worse than
92.12% of 495 companies
in the Medical Devices & Instruments industry
Industry Median: 1.83 vs LTS:0MR5: 8.98

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

CellaVision AB's adjusted book value per share data for the three months ended in Mar. 2025 was kr35.156. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is kr20.86 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


CellaVision AB Cyclically Adjusted PB Ratio Historical Data

The historical data trend for CellaVision AB's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CellaVision AB Cyclically Adjusted PB Ratio Chart

CellaVision AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.63 29.45 15.91 12.29 10.96

CellaVision AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.35 13.50 15.33 10.96 8.15

Competitive Comparison of CellaVision AB's Cyclically Adjusted PB Ratio

For the Medical Devices subindustry, CellaVision AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CellaVision AB's Cyclically Adjusted PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where CellaVision AB's Cyclically Adjusted PB Ratio falls into.


;
;

CellaVision AB Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

CellaVision AB's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=186.10/20.86
=8.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CellaVision AB's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, CellaVision AB's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=35.156/132.8245*132.8245
=35.156

Current CPI (Mar. 2025) = 132.8245.

CellaVision AB Quarterly Data

Book Value per Share CPI Adj_Book
201506 6.045 99.995 8.030
201509 7.031 100.228 9.318
201512 7.694 100.276 10.191
201603 8.137 100.751 10.727
201606 7.219 101.019 9.492
201609 7.815 101.138 10.263
201612 8.644 102.022 11.254
201703 9.768 102.022 12.717
201706 9.178 102.752 11.864
201709 9.494 103.279 12.210
201712 10.098 103.793 12.923
201803 10.644 103.962 13.599
201806 9.978 104.875 12.637
201809 10.852 105.679 13.640
201812 12.174 105.912 15.267
201903 13.228 105.886 16.593
201906 12.994 106.742 16.169
201909 13.708 107.214 16.982
201912 14.606 107.766 18.002
202003 16.053 106.563 20.009
202006 16.716 107.498 20.654
202009 17.333 107.635 21.389
202012 18.012 108.296 22.092
202103 19.420 108.360 23.805
202106 19.783 108.928 24.123
202109 20.983 110.338 25.259
202112 22.777 112.486 26.895
202203 24.525 114.825 28.369
202206 24.587 118.384 27.586
202209 25.403 122.296 27.590
202212 26.900 126.365 28.275
202303 27.850 127.042 29.118
202306 27.657 129.407 28.388
202309 28.421 130.224 28.989
202312 30.035 131.912 30.243
202403 31.811 132.205 31.960
202406 30.996 132.716 31.021
202409 32.193 132.304 32.320
202412 34.200 132.987 34.158
202503 35.156 132.825 35.156

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CellaVision AB  (LTS:0MR5) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


CellaVision AB Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of CellaVision AB's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CellaVision AB Business Description

Traded in Other Exchanges
Address
Mobilvagen 12, Lund, SWE, 22362
CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application, and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China, and Japan. The company derives the majority of its revenue from the sale of analyzers or software.

CellaVision AB Headlines

No Headlines